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Podocytes have a significant role in establishing selective
permeability of the glomerular filtration barrier. Sustained
renin–angiotensin–aldosterone system activation is crucial
to the pathogenesis of podocyte injury, but the mechanisms
by which angiotensin II modulates podocyte survival
due to physiological or injurious stimuli remain unclear.
Here, we used proteomic analysis to find new mediators of
angiotensin II–induced podocyte injury. Antioxidant protein
peroxiredoxin 2 expression was decreased in cultured
podocytes stimulated with angiotensin II. Peroxiredoxin 2
was found to be expressed in podocytes in vivo, and its
expression was decreased in the glomeruli of rats transgenic
for angiotensin II type 1 receptors in a podocyte-specific
manner, or in rats infused with angiotensin II. Downregulation
of peroxiredoxin 2 in podocytes resulted in increased reactive
oxygen species release, protein overoxidation, and inhibition
of the Akt pathway. Both treatment with angiotensin II
and downregulation of peroxiredoxin 2 expression led to
apoptosis of podocytes. Thus, peroxiredoxin 2 is an important
modulator of angiotensin II–induced podocyte injury.
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The filtration barrier of the kidney comprises glomerular
endothelial cells, the glomerular basement membrane, and
podocytes. The foot processes of neighboring podocytes form
the slit diaphragm, which has a major role in maintenance of
the glomerular filtration barrier.1 Podocyte injury leads to
proteinuria, a hallmark of glomerular diseases, which cause
90% of the end-stage kidney disease in the United States.2
Because terminally differentiated podocytes cannot replicate,
podocyte loss is an important event in the progression to
glomerulosclerosis and end-stage kidney disease.2,3
Within the glomerulus, angiotensin II (Ang II) decreases
the ultrafiltration coefficient and modulates glomerular capillary
permselectivity, leading to proteinuria. Ang II concentrations
in the tubular ultrafiltrate are up to 1000-fold greater than
those in the systemic blood circulation, indicating intrarenal
production of Ang II.4 Podocytes contribute to intrarenal
Ang II levels because they possess a local renin–angiotensin
system that includes Ang II type 1 receptors (AT1Rs).5–7
A large body of evidence supports the idea that inhibition of
the renin–angiotensin–aldosterone system mitigates protein-
uria and progression of chronic kidney disease.4,8 Because
the antiproteinuric and antihypertensive effects of AT1R
blockers seem to be independent, it has been suggested that
Ang II directly influences podocyte functions.9 Indeed,
Ang II increases intracellular calcium activity, causes an
Rac-dependent and reactive oxygen species (ROS)-mediated
F-actin cytoskeleton rearrangement, and results in podocyte
injury.9,10 In addition, in vivo overexpression of AT1R in
podocytes causes podocyte damage, proteinuria, and marked
glomerulosclerosis.11 Thus, inhibition of renin–angiotensin–
aldosterone system prevents many deleterious processes in
podocytes, thereby reducing the extent of injury.10 Because
renin–angiotensin–aldosterone system inhibition is so impor-
tant for renal and podocyte protection, it is vital to elucidate
the signaling events and proteins involved in Ang II–mediated
injury. In this study, we used proteomic analysis to show that
the antioxidant protein peroxiredoxin 2 (Prdx2) participates
in AT1R-mediated effects on podocytes.
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RESULTS
Two-dimensional difference gel electrophoresis proteomics
of podocytes stimulated with Ang II
Proteomic analysis of Ang II–stimulated (100 nmol/l, 24 h)
cultured AT1R podocytes provided an overview of differ-
ential protein expression levels in AT1R signaling. Using the
Ettan DIGE system, we identified 21 proteins of interest that
showed significant differential expression in podocytes
with and without Ang II treatment (Figure 1a). Table 1
presents a summary of these proteins and their general
functions. Proteomic results show that both cytosolic enzymes
involved in glycolysis (a-enolase, phosphoglycerate kinase 1,
transketolase, and triosephosphate isomerase) and a mito-
chondrial enzyme methylcrotonoyl-coenzyme A carboxylase 2 b
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Figure 1 | Two-dimensional fluorescence difference gel electrophoresis (2D DIGE) and proteomic analysis identified that
angiotensin II (Ang II) signaling downregulates peroxiredoxin 2 (Prdx2) expression in podocytes. (a) Monitoring of Ang II–induced
changes in protein expression pattern of cultured Ang II type 1 receptor podocytes by 2D DIGE. The 15 spots labeled in red were
consistently 41.6-fold downregulated (Po0.05), whereas the 6 spots labeled in yellow were consistently 41.6-fold upregulated (Po0.05)
after Ang II stimulation (100 nmol/l, 24 h) compared with vehicle-treated control in a representative CyDye 2D gel image (n¼ 4). Each
spot analyzed using mass spectrometry is identified with a UniProtKB accession number. (b) Comparative parts (left panel) and three
dimensional–computed spot signal intensity reconstruction (right panel; v, vehicle; A, Ang II) of the red rectangle–surrounded areas
in a; downregulated Prdx2 (theoretical pI:5.2; molecular weight: 21,179 Da) expression in Ang II–treated cells versus vehicle-treated
cells. (c) In quantitative analysis, differential expression of Prdx2 (a 1.69-fold decrease) was confirmed statistically by Student’s t-test
(#statistically significant with Po0.05). pI, isoelectric point.
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are significantly upregulated. Therefore, podocyte metabolic
rates and energy consumption may be increased after Ang II
stimulation. Ang II is known to induce cytoskeletal
rearrangements in differentiated podocytes, which likely
explains this increased energy consumption.10 In contrast,
Ang II treatment downregulated the expression of proteins
involved in protein biosynthesis, the stress-response process,
and neo-synthesis of cytoskeleton-related proteins. Reduced
synthesis of these possibly vital proteins, especially under
conditions of high metabolism and energy consumption,
may lead to podocyte injury.
Downregulation of Prdx2 in Ang II–treated podocytes
Figure 1b and c and the red rectangle-surrounded areas in
Figure 1a illustrate a protein spot with a molecular weight of
22 kDa, and the isoelectric point value of 5.2 decreased 1.7-
fold in signal intensity after Ang II treatment compared with
control cells. This protein was identified by mass spectrom-
etry as Prdx2 (UniProtKB accession no. Q61171), which was
initially reported to be a major antioxidant protein.12
To validate the Ang II–dependent decrease in Prdx2
expression, we performed a western blot analysis of protein
lysates from Ang II–stimulated and non-stimulated cultured
AT1R podocytes. Ang II downregulated the expression level
of Prdx2 in AT1R podocytes to a similar extent (0.61±0.07-
fold compared with non-stimulated cells) as by difference gel
electrophoresis (DIGE) proteomics (Figure 2a). The AT1R-
specific inhibitor losartan but not the AT2R-specific inhibitor
PD123319 abolished the Ang II–dependent reduction of
Prdx2 expression, indicating an AT1R-specific effect. We
performed immunofluorescence microscopic analysis of
Prdx2 protein localization in the glomeruli of human
kidneys. Double immunostaining with either of the podo-
cyte-specific markers Wt-1 or podocin, and a Prdx2-specific
antibody indicated that podocytes abundantly express Prdx2
in vivo (Figure 2b).
Podocyte-specific AT1R transgenic rats (Neph-hAT1
TGRs) develop proteinuria and glomerulosclerosis.11 Figure
2c shows that Prdx2 expression was 0.51±0.07-fold lower in
the glomeruli of 4-week-old Neph-hAT1 TGRs compared
with that in glomeruli from age-matched wild-type (WT)
littermates. No difference in Prdx2 expression level was
detected in the renal tubules (Figure 2c).
Increased cellular oxidative stress is associated with Prdx2
downregulation in podocytes
Recently, we showed that Ang II increases ROS levels in
podocytes.10 The physiological significance of the antioxidant
Prdx2 is unclear and little is known about whether Prdx2
downregulation affects the cellular redox balance in podo-
cytes. Therefore, we examined the expression over time of the
overoxidized form of Prdx, Prdx-SO3, in which the
peroxidatic cysteine of Prdx is oxidized from thiol to sulfonic
acid.13,14 Figure 3a shows that the Ang II–dependent
downregulation of Prdx2 correlates with increased expression
of overoxidized Prdx-SO3 and Prdx2-SO3, suggesting that
ROS increase oxidative stress in podocytes.
To elucidate the effects of Prdx2 downregulation in
podocytes, small interfering RNAs (siRNAs) targeting Prdx2,
Prdx1, and a scrambled short hairpin sequence (control)
were stably expressed in cultured podocytes by a retroviral-
based gene delivery method. Sustained suppression of Prdx2
expression (downregulated B60% compared with WT or
scrambled siRNA-transfected podocytes) was verified by
immunoblotting (Figure 3b). Downregulation of Prdx2
but not Prdx1 increased the expression of the oxidative
stress-responsive protein catalase. Both Ang II treat-
ment and Prdx2 (si-Prdx2) knockdown induced signifi-
cant increases of intracellular ROS in an AT1R-dependent
manner (Ang II: 4.38±0.06-fold compared with non-
stimulated cells; see Figure 3c; Prdx2: 3.77±0.66-fold
compared with scrambled siRNA-transfected or WT podo-
cytes; see Figure 3d). The oxidative effects of Prdx2 knock-
down could be eliminated by treating the cells with the
free-radical scavenger dimethylthiourea (Figure 3d, panel iii).
Interestingly, knockdown of Prdx1, which has 91% amino-
acid sequence identity to Prdx2,15 increases ROS levels only
slightly (data not shown).
Table 1 | Summary of proteins differentially expressed after
stimulation with Ang II
UniProtKB
accession no. Annotation
Change
(-fold) P-value
Metabolic enzymes
P17182 a-Enolase +2.10 3.0e006
B2RUK5 Methylcrotonoyl-coenzyme A
carboxylase 2 b
+1.91 0.013
P09411 Phosphoglycerate kinase 1 +1.73 0.0040
P40142 Transketolase +1.64 0.0071
P17751 Triosephosphate isomerase +1.63 4.1e008
Protein biosynthesis
Q3TJZ1 Eukaryotic translation
elongation factor 2
+1.96 9.0e005
Q3TVD2 Calreticulin 1.92 0.0005
Q9D1M0 Protein SEC13 homolog 1.82 5.3e006
P09103 Protein disulfide-isomerase 1.68 3.3e007
Q9Z247 Peptidyl-prolyl cis–trans
isomerase FKBP9
1.66 8.1e005
P14206 40S ribosomal protein SA 1.61 4.5e005
Stress/damage response
Q61171 Peroxiredoxin 2 1.69 0.00017
Q9WV39 DNA damage-binding protein 1 1.65 0.00044
Q80X75 Hypoxia upregulated protein 1 1.62 0.00019
P08113 Endoplasmin (heat shock
protein 90 kDa b member 1)
1.62 0.00023
Cytoskeleton associated
P20152 Vimentin 1.67 6.3e006
P58771 Tropomyosin a-1 chain 1.66 8.2e006
P68372 Tubulin b-2C chain 1.65 6.6e006
Q6IRU2 Tropomyosin a-4 chain 1.62 1.3e005
Other
P62880 Guanine nucleotide-binding
protein subunit b-2
1.71 3.1e008
Q61207 Sulfated glycoprotein 1 1.60 0.0097
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Downregulation of Prdx2 and associated ROS increase
mediates Ang II–induced apoptosis in podocytes
Ang II is known to mediate apoptosis.16,17 However, the role
of Ang II–induced ROS formation and its molecular
mechanisms in podocyte survival and apoptosis remain
unknown. Figure 4a shows that Ang II treatment increased
cleaved caspase 3 expression in cultured AT1R podocytes
compared with non-stimulated WT and AT1R cells. Losartan
or dimethylthiourea significantly attenuated Ang II–induced
cleaved caspase 3 expression, indicating the presence of an
AT1R-specific and ROS-mediated signaling mechanism in
podocytes.
Moreover, quantitative analysis of flow cytometric
Annexin V-fluorescein isothiocyanate (FITC)/propidium
iodide (PI) staining (Figure 4b) showed that Ang II induced
a significant increase of apoptosis in cultured AT1R
Ve
hic
le
WT
Prdx2
GAPDH
Fo
ld
 o
f d
ec
re
as
e
(P
rdx
2)
AT1R Podocyte
1
# #
0.5
0
(i) Prdx2 (ii) Wt-1
(v) Podocin
(iii) Merge
(vi) Merge
50 μm
50 μm(iv) Prdx2
Glom
Prdx2
GAPDH
Tubu
1
#
Glom Tubu
0.5
0Fo
ld
 o
f d
ec
re
as
e
(P
rdx
2)
Wi
ld-
typ
e r
at
hA
T1
 TG
R
Wi
ld-
typ
e r
at
hA
T1
 TG
R
Wi
ld-
typ
e r
at
hA
T1
 TG
R
Wi
ld-
typ
e r
at
hA
T1
 TG
R
Ve
hic
le
An
g I
I 2
4 h
An
g I
I +
 los
art
an
An
g I
I +
 PD
12
33
19
Ve
hic
le 
(WT
)
Ve
hic
le 
(AT
1R
)
An
g I
I 2
4 h
An
g I
I +
 los
art
an
An
g I
I +
 PD
12
33
19
Figure 2 |Peroxiredoxin 2 (Prdx2) is downregulated with angiotensin II (Ang II) type 1 receptor (AT1R) signaling both in vitro
and in vivo. (a) Representative immunoblotting (left panel) and quantitative analysis (right panel) of Prdx2 expression in cultured
AT1R podocytes treated with Ang II (100 nmol/l, 24 h) combined with different inhibitors (losartan, AT1R inhibitor, 200 nmol/l; PD123319,
AT2R inhibitor, 200 nmol/l); untreated wild-type podocytes were used as a second control (WT: wild-type cultured podocyte; AT1R
podocyte: human AT1R stable expression podocyte cell line; #statistically significant with Po0.05 compared with vehicle-treated AT1R cells).
(b) Glomerular expression of Prdx2 is observed in a podocyte pattern in human kidney sections. Colocalization (iii and vi, yellow color
in merged images) of Prdx2 (i and iv, in green) and Wilms’ tumor-1 protein (ii, in red) or podocin (v, in red) in immunofluorescent staining
of human kidney cryosections suggested that in situ podocytes expressed Prdx2 protein. (c) Representative immunoblotting (left panel)
and quantitative analysis (right panel) of Prdx2 expression in kidney tissues from 4-week-old Neph-hAT1 transgenic rats (TGRs) and
age-matched littermates (WT). Glomerular expression of Prdx2 was significantly lower in Neph-hAT1 TGRs (0.51±0.07-fold; #statistically
significant with Po0.05 versus WT Glom, n¼ 3). Tubular Prdx2 expression levels did not differ significantly between Neph-hAT1 TGRs and
WT rats. Glom, glomerulus; Tubu, tubule. Immunoblotting of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) reveals equal loading
of all lanes.
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podocytes (2.22±0.27-fold increase versus vehicle-treated
AT1R cells, Figure 4c). This effect could be inhibited by
either pretreatment with losartan or coincubation with
dimethylthiourea, suggesting that Ang II induces apoptosis
in podocytes via an AT1R-specific and ROS-mediated
signaling pathway.
The crucial role of Prdx2 downregulation and associated
increased ROS levels in Ang II–induced podocyte apoptosis is
illustrated in Figure 4d. In flow cytometric Annexin V-FITC/
PI staining, knockdown of Prdx2 protein expression in
cultured podocytes (si-Prdx2 cells) was observed to increase
apoptosis significantly compared with control cells (3.07±
0.36-fold). Neither Prdx1-specific knockdown (si-Prdx1)
podocytes nor scramble siRNA-transfected (si-scram) cells
exerted these significant apoptotic effects.
Ang II–driven Akt dephosphorylation is involved in Prdx2
downregulation-mediated apoptosis in podocytes
Akt, or protein kinase B, is a serine/threonine kinase that is
critical in controlling mammalian cell survival and apopto-
sis.18 Failure to phosphorylate Akt has been recently reported
to promote podocyte/kidney injury in a diabetic mouse
model19 and in a renin–angiotensin system overactivating
transgenic Ren2 rat model.20 In this study, we examined
phosphorylation at the Ser-473 position of Akt in Ang II–
stimulated (100 nmol/l) AT1R podocytes. Figure 5a illustrates
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Figure 3 |Angiotensin II (Ang II) stimulation and downregulated peroxiredoxin 2 (Prdx2) expression increases intracellular reactive
oxygen species (ROS) level and protein overoxidation in podocytes. (a) The left plot illustrates time-dependent Prdx2 expression
downregulation and the associated increase of overoxidized Prdx-SO3 in cultured Ang II type 1 receptor (AT1R) podocytes with Ang II
(100 nmol/l) treatment, whereas the right plot summarizes the time-dependent relative change in Prdx2 expression and the percentage
of overoxidized Prdx2 (Prdx2-SO3) in Ang II–treated cells (n¼ 3; #statistically significant with Po0.05). (b) (Left panel) Using a short
hairpin sequence targeting mouse Prdx2 nucleotide sequence positions 233–251 and a retroviral gene delivery method, Prdx2 expression
level could be knocked down to 0.39±0.05-fold in cultured podocytes (si-Prdx2 cells) versus control cells. To exclude off-target effect,
a second short hairpin sequence targeting mouse Prdx1 nucleotide sequence positions 158–177 (producing 0.53±0.13-fold knockdown)
and a scrambled short hairpin sequence were stably transfected to cultured podocytes. Upregulation of catalase, an oxidative stress-
responsive protein, was additionally observed in Prdx2 knockdown podocytes. Immunoblotting of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) reveals equal loading of all lanes. Right and left lower plots revealed quantitative analysis (n¼ 3; #statistically
significant with Po0.05). (c, d) Intracellular ROS level in adherent cultured podocytes was measured with a dihydroethidium (DHE)
assay. Ang II (100 nmol/l, 24 h) treatment induced a 4.38±0.06-fold increase in ROS level compared with vehicle-treated cells (c), and
this response could be effectively suppressed by preincubation with an AT1R-specific inhibitor (losartan, 200 nmol/l). In d, specifically
knocking down Prdx2 expression in cultured podocytes (si-Prdx2) also resulted in a 3.77±0.66-fold increase of ROS level compared
with scrambled sequence small interfering RNA-transfected (si-scram) or control (wild type) cells. In addition, the ROS-increasing effects
of Prdx2 knockdown could be eliminated by treatment with the free-radical scavenger dimethylthiourea (iii, DMTU, 10mmol/l, 2 h; n¼ 3;
#statistically significant with Po0.05).
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that Ang II treatment decreased Akt phosphorylation in
podocytes in a time-dependent manner. In contrast, the
activity of extracellular signal-regulated kinase (Erk), another
proposed regulator of mammalian cell lifespan,21 is signifi-
cantly upregulated in Ang II–treated podocytes compared
with vehicle-treated cells.
To further explore the mechanisms linking Prdx2 down-
regulation and Akt dephosphorylation to Ang II–induced
apoptosis, we examined phosphorylation of Akt and Erk in
cultured Prdx2 knockdown podocytes. Figure 5b illustrates that
Prdx2 knockdown reduces Akt phosphorylation in Ang II–
treated podocytes compared with control cells. However, no
change in Erk phosphorylation was observed in Prdx2 knock-
down podocytes. This indicates that Akt but not Erk signaling
is modulated by Prdx2. In agreement with these experiments,
treatment of podocytes with a phosphatidylinositol 3-kinase
inhibitor (LY294002) significantly increased cleaved caspase
3 (Figure 5c) and Annexin V-FITC/PI staining (Figure 5d,
measured by flow cytometry) in cultured podocytes.
Downregulation of glomerular Prdx2 correlates with
oxidative stress and apoptosis in Ang II–infused rats
To further confirm the biological role of Ang II in regulating
Prdx2 expression, we examined its expression in glomeruli of
rats that have been infused with Ang II. Sustained low-dose
Ang II infusion (150 ng/kg/min) increased urinary albumin
excretion and reduced creatinine clearance at 7 and 14 days
(Figure 6a). Figure 6b and c shows that in comparison with
vehicle Ang II treatment resulted in glomerular Prdx2
downregulation, decreased Akt phosphorylation, upregula-
tion of Prdx-SO3, caspase 3, and cleaved caspase 3 expression.
After Ang II infusion, the expression level of other oxidative-
defense proteins was either increased (Prdx1, catalase, and
GPx4) or had no significant change (SOD1, SOD2, and
GPx1). The association between reduction of the expression
of Prdx2 in podocytes and apoptosis is demonstrated by
immunohistostaining of Prdx2 and cleaved caspase 3 in
glomeruli from Ang II–infused and vehicle-treated rats,
respectively (Figure 6d and e).
DISCUSSION
Both Ang II enhancement of NADPH-dependent oxidase
activity and the role of ROS in regulating renal function
during Ang II infusion have been well described;22,23
however, little is known about the functions of other oxidant
and antioxidant proteins involved in the effects of Ang II in
podocytes.24
In this study, we used proteomic analysis and showed that
in addition to altering the expression of other metabolic,
cytoskeletal, and stress-responsive proteins, Ang II treatment
downregulates the expression of the antioxidant protein
Prdx2 in podocytes. The Prdx family of peroxidases is
currently known to comprise six mammalian isoforms that
catalyze the peroxide reduction of H2O2, organic hydroper-
oxides, and peroxynitrite, thus protecting cells against
oxidative damage.13,25 Experimental and clinical studies have
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Figure 4 |Downregulation of peroxiredoxin 2 (Prdx2) mediates
angiotensin II (Ang II)–induced apoptosis in podocytes.
(a) Representative immunoblotting (left panel) and quantitative
analysis (right panel) show that Ang II (100nmol/l, 24h) triggers
caspase 3 activation in cultured podocytes. Ang II–induced cleaved
caspase 3 increase (1.76±0.06-fold; n¼ 3; #statistically significant
with Po0.05, Ang II– versus vehicle-treated Ang II type 1 receptor
(AT1R) cells) could be suppressed either by pretreatment with an
AT1R-specific inhibitor (losartan, 200nmol/l) or by coincubation with
a free-radical scavenger (dimethylthiourea (DMTU), 10mmol/l; n¼ 3;
#statistically significant at Po0.05 compared with the vehicle-treated
AT1R cell group). (b–d) Fluorescence-activated cell sorting analysis
via Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI)
staining was used to observe the induction of apoptosis. Cells in the
lower right quadrant indicate Annexin V-positive/PI-negative early
apoptotic cells. Representative plots in b revealed that Ang II
stimulation (100nmol/l, 24h) induced a greater degree of apoptosis
than that seen in untreated AT1R cells. (c) Quantitative analysis of
flow cytometric Annexin V-FITC/PI staining measurements illustrate
that Ang II induced a 2.22±0.27-fold increase in apoptosis in
cultured AT1R podocytes compared with vehicle-treated cells.
This effect could also be eliminated either by pretreatment with
an AT1R-specific inhibitor (losartan; 200nmol/l) or by coincubation
with a free-radical scavenger (DMTU, 10mmol/l; n¼ 3; #statistically
significant at Po0.05 compared with the vehicle-treated AT1R cell
group). (d) Quantitative analysis of flow cytometric Annexin V-FITC/PI
staining measurements showed that small interfering RNA (siRNA)
knockdown of Prdx2 protein expression in cultured podocytes
(si-Prdx2 cells) caused a 3.07±0.36-fold increase in apoptosis
compared with control cells (#statistically significant at Po0.05),
and the effect could be eliminated by coincubation with a free-
radical scavenger (DMTU, 10mmol/l; f: statistically significant at
Po0.05 versus si-Prdx2 cells without DMTU). Neither Prdx1-specific
knockdown (si-Prdx1) podocytes nor scramble siRNA-transfected
(si-scram) cells exerted significant apoptotic effects. A minimum
of three independent experiments were conducted (n¼ 3).
GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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shown that Prdx family members modulate many cellular
processes by switching over the oxidative–reductive environ-
ment within cells.13,26–28 The functional roles of Prdx2 in
erythrocyte lifespan,29 vascular remodeling,30 and cardiovas-
cular diseases31 have been recently described.
Little is known about the cellular distribution and
function of Prdx2 in the kidney. We showed that Prdx2 is
expressed in vivo in podocytes and that glomerular Prdx2
expression was reduced in AT1R transgenic rats. As a better
approach to the in vivo situation, we conducted experiments
in rats that were treated with Ang II. In this animal model, a
minimal increase of blood pressure and doubling of the
NADH oxidase activity in vessels has been described by
others.32–34 Ang II treatment resulted in glomerular Prdx2
downregulation, decreased Akt phosphorylation, upregula-
tion of Prdx-SO3, caspase 3, and cleaved caspase 3 expression,
suggesting that the effect of Ang II on Prdx2 has a biological
in vivo significance.
These data suggest that Prdx2 is involved in AT1R-mediated
glomerular functions. The peroxidatic catalytic cysteine of
Prdx is highly susceptible to overoxidation to sulfonic acid
(Prdx-SO3) as a result of excess ROS/oxidative status in
podocytes, which results in loss of activity.35 To determine
whether Prdx2 is also a sensor and transmitter of redox signals,
we examined the level of overoxidized Prdx (Prdx-SO3) in
Ang II–treated podocytes and found that increases in Prdx-SO3
and Prdx2-SO3 were associated with Ang II–induced Prdx2
downregulation, indicating a switch to an excess of ROS and
oxidative stress status. In addition, Ang II treatment or
knockdown of Prdx2 increases ROS levels in podocytes.
A growing body of evidence supports the hypothesis
that podocyte apoptosis is a major cause of reduced podo-
cyte numbers, which leads to proteinuria and/or glome-
rulosclerosis. In vitro and in vivo studies have shown that
Ang II induces podocyte apoptosis.36 In this study, we
showed that both Ang II treatment and Prdx2 knockdown
leads to apoptosis of podocytes, and that this apoptosis
could be prevented by a free-radical scavenger. Prdx2-
induced protection from H2O2-induced apoptosis has
been described in other cell types, such as thyroid cells.37
In addition, a correlation between loss of Prdx2 and
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Figure 5 |Attenuated activity of the Akt pathway associated
with peroxiredoxin 2 (Prdx2) downregulation is involved
in angiotensin II (Ang II)–induced apoptotic signaling.
(a) Representative immunoblotting (left plot) and quantitative
analysis (right plot) of Akt and Erk pathway activity in cultured
Ang II type 1 receptor (AT1R) podocytes stimulated with Ang II
(100 nmol/l) in a time-course manner. Akt phosphorylation at
Ser-473 (pAkt) decreased significantly after Ang II treatment at 6 h
(0.70±0.06-fold), 12 h (0.67±0.04-fold), and 24 h (0.43±0.06-fold)
compared with the vehicle-treated group (n¼ 3; #all values
were Po0.05 versus vehicle-treated cells). Erk phosphorylation
(pErk) at Thr202/Tyr204 of Erk1 (Thr185/Tyr187 of Erk2) in
Ang II–treated podocytes was significantly upregulated in
each time point compared with vehicle-treated cells (n¼ 3;
#all statistically significant at Po0.05 versus vehicle-treated cells).
(b) Representative immunoblotting (left plot) and quantitative
analysis (right plot) of Akt and Erk pathway activity in cultured
Prdx knockdown podocytes. Small interfering RNA (siRNA)
knockdown of Prdx2 protein expression (si-Prdx2) in cultured
podocytes caused a 0.46±0.12-fold decrease of Akt phosphorylation
compared with control cells (n¼ 3; #statistically significant at
Po0.05), whereas neither Prdx1-specific knockdown (si-Prdx1)
podocytes nor scramble siRNA-transfected (si-scram) cells exerted
significant effects. No difference in Erk phosphorylation level
was observed in Prdx2 knockdown podocytes compared with
control cells. (c) Representative immunoblotting showed that
concentration-dependent Akt pathway inhibition by treating
cultured podocytes with a phosphatidylinositol 3-kinase inhibitor
(LY294002, 24 h) causes significant increase in cleaved caspase 3
versus that in vehicle-treated cells. Immunoblotting of glyceraldehyde
3-phosphate dehydrogenase (GAPDH) reveals equal loadings
for all lanes (n¼ 3). (d) Quantitative analysis of flow cytometric
Annexin V-fluorescein isothiocyanate/propidium iodide staining
measurements showed that concentration-dependent inhibition
of the Akt pathway with LY294002 (24 h) in cultured podocytes
caused a 1.75±0.12-fold (0.5mmol/l), 2.05±0.19-fold (1.0 mmol/l),
and 3.25±0.30-fold (2.0 mmol/l) increase in apoptosis compared
with vehicle-treated cells (n¼ 3; #statistically significant at Po0.05).
WT, wild type.
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podocyte apoptosis and proteinuria was also demonstrated
in the Ang II–infused rats.
Akt and Erk 1/2 seem to have important roles in the
signaling of the slit diaphragm and in podocyte function. The
slit diaphragm proteins nephrin and CD2AP interact with
phosphatidylinositol 3-kinase p85, increasing Akt activity
and decreasing apoptosis.38 Galectin-1 (Gal-1), a newly described
slit diaphragm protein, triggers increased tyrosine phosphor-
ylation of nephrin, which activates Erk 1/2.39 In contrast,
Neph1 has been shown to negatively regulate Erk 1/2 signaling
in podocytes.40 Although the role of these kinases in glomerular
diseases is not fully understood, it has been suggested in a
diabetic mouse model that failure to phosphorylate Akt
causes podocyte apoptosis.19 Podocyte injury mediated by
p38 MAP kinase and Erk 1/2 has been observed in several
experimental models of glomerular disease.41 In this study,
we showed that Ang II decreases Akt phosphorylation and
increases Erk 1/2 phosphorylation in podocytes. Knockdown
of Prdx2 reduced Akt phosphorylation but did not affect Erk
phosphorylation, suggesting that Prdx2 inhibits the Akt but
not the Erk pathway in podocytes. Interestingly, activation of
Akt has been reported recently in Prdx1-deficient fibroblasts
and epithelial cells.42 It has been shown that transient over-
expression of Prdx2 inhibits epidemal growth factor-induced
phosphorylation of Akt in HeLa cells,43 suggesting a different
role of Prdx2 in regulation of the Akt pathway in these cells.
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AT1R signaling in podocytes thus activates Rac-1 and
NADPH oxidase to produce additional ROS and may
downregulate the antioxidant protein Prdx2 to maintain an
oxidative environment that favors signal propagation. In a
‘floodgate’ mechanism,13 Prdx2 consumes low levels of ROS
through its peroxidase activities, but is inactivated by higher
ROS concentrations and, thus, provides a localized zone in
which ROS are available to react with other targets and
propagate the signal. In conclusion, our findings indicate that
Prdx2 mediates podocyte signaling and regulates AT1R-
mediated injury. In the future, activation of Prdx2 may
supplement renin–angiotensin–aldosterone system blockade
as a strategy for treating chronic kidney diseases.
METHODS
Antibodies and reagents
Losartan potassium was gifted by Merck (Whitehouse Station, NJ).
Ang II, PD123319, and dimethylthiourea were purchased from
Sigma-Aldrich (Munich, Germany). LY294002 was purchased from
Merck-Calbiochem (Darmstadt, Germany). Antibodies specific for
Prdx2, Prdx1, catalase, superoxide dismutase 1/2, glutathione
peroxidase 1/4, podocin, and peroxiredoxin-SO3 were purchased
from AbFRONTIER (Seoul, South Korea). Antibodies for phospho-
Akt (Ser 473), Akt, caspase 3, cleaved caspase 3, and phospho-Erk
were obtained from Cell Signaling Technology (Danvers, MA).
Antibodies for Erk 1 and Erk 2 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody to
Wilms’ tumor-1 was obtained from DAKO (Glostrup, Denmark).
Alexa Fluor 488-conjugated goat anti-rabbit antibody, Alexa Fluor
594-conjugated goat anti-mouse antibodies, propidium iodide, and
dihydroethidium (DHE) were obtained from Molecular Probes
(Darmstadt, Germany). FITC-conjugated Annexin V antibody was
purchased from BD Biosciences (Erembodegem, Belgium).
Cell culture, animals, and experimental protocol
The two conditionally immortalized mouse podocyte cell lines used
in the current study, WT podocytes and AT1R podocytes (cells
stably expressing functional human AT1Rs), have previously been
described in detail.10,44 In the in vivo Ang II model, rats were infused
with Ang II (150 ng/kg/min) for 7 or 14 days using mini-osmotic
pumps (ALZET, 2002, Cupertino, CA) implanted subcutaneously as
described in the literature.33,34 Serum and urine creatinine were
measured by a picric acid-based colorimetric autoanalyzer. Urine
albumin was detected by the immunoturbidimetric method. Podo-
cyte-specific human AT1R transgenic rats (Neph-hAT1 TGRs) and
age-matched WT littermates were previously described in detail and
develop significant albuminuria and concurrent glomerular structural
changes from 8 to 15 weeks of age.11 Glomeruli were isolated from rat
kidneys via sequential sieving as described previously.10 All studies
were approved by the institutional animal care review committee and
conducted according to government regulations.
Two-dimensional fluorescence DIGE system and proteomics
For two-dimensional (2D) polyacrylamide gel-based analysis,
podocytes were harvested and homogenized in 2D electrophoresis
lysis buffer. Protein samples from vehicle- and Ang II–treated
podocytes were labeled with Cy3- and Cy5-CyDye DIGE Fluor dyes
(GE Healthcare, Munich, Germany), respectively, for 30min at 4 1C.
A pooled sample of vehicle- and Ang II–treated podocyte lysates was
similarly labeled with Cy2-CyDye DIGE Fluor dye for use as an
internal control.
Cy3-, Cy5-, and Cy2-labeled samples (50 mg each) were
isoelectrically focused on an immobilized pH gradient strip
(24 cm; pH 3–10, non-linear) using a PROTEAN IEF cell
(Bio-Rad, Munich, Germany) to reachB80,000 total voltage hours.
After focusing, strips were equilibrated and applied to a 12%
polyacrylamide gel for electrophoresis under a constant current.
Samples were prepared and then electrophoresed in triplicate.
A Typhoon scanner in fluorescence mode (GE Healthcare) was
used to obtain Cy3, Cy5, and Cy2 images of analytical gels. Images
were analyzed using DeCyder software (GE Healthcare) to identify
protein spots exhibiting statistically significant changes between
groups using Student’s t-test and analysis of variance. Preparative
gels (loaded to B1mg protein of lysate per gel) were then fixed in
30% ethanol and 7.5% acetic acid for 2 h, followed by Coomassie
staining overnight for total protein visualization. Identified proteins
of interest were picked from preparative gels as gel plugs.
Figure 6 |Downregulation of glomerular peroxiredoxin 2 (Prdx2) correlates with oxidative stress and apoptosis in angiotensin II
(Ang II)–infused rats. The control group (Sprague–Dawley rat, n¼ 6) was administered only saline, and the experimental group was
subcutaneously infused with Ang II via an osmotic minipump from 6 weeks of age for 7 days (n¼ 6) and 14 days (n¼ 6). (a) Body weight
changes (shown as a percentage of the initial weight), creatinine clearance (ClearanceCr), urine albumin creatinine excretion ratio (UACR),
serum urea nitrogen levels, and preinfusion and after infusion mean arterial pressures (MAP, #statistically significant with Po0.05 compared
with the vehicle-treated group; f: statistically significant with Po0.05 compared with preinfusion blood pressure level in each group).
(b) Representative immunoblotting of Prdx2, Prdx1, Prdx-SO3, cleaved caspase 3 expression, Akt phosphorylation, and expression level
of other reactive oxygen species-protective enzymes (catalase, SOD1, SOD2, GPx1 and GPx4) in glomerular extract of rats treated with Ang II
at different time points. SOD, superoxide dismutase; GPx, glutathione peroxidase. (c) Quantitative analysis of immunoblotting showed that
glomerular Prdx2 expression decreased significantly after Ang II infusion at 7 (0.69±0.20-fold) and 14 days (0.56±0.11-fold) compared with
the vehicle-treated group. Ang II–dependent downregulation of Prdx2 in rat glomeruli correlates with increased expression of Prdx-SO3
(overoxidized form of Prdx), suggesting that Ang II increases the oxidative stress status in vivo. Ang II also increased both cleaved caspase 3
(1.34±0.20-fold at day 7 and 1.73±0.11-fold at day 14) and caspase 3 expression levels (1.26±0.18-fold at day 7 and 1.59±0.11-fold
at day 14) in rat glomerular extracts (n¼ 3; #statistically significant with Po0.05 compared with vehicle-treated rats). (d) Representative
immunohistochemical staining for glomerular Prdx2 and cleaved caspase 3 expression in Ang II– and vehicle-infused rat kidneys obtained
on day 14. Prdx2 staining in a podocyte cytoplasmic pattern was observed to decrease following Ang II treatment and to correlate with
increased glomerular cleaved caspase 3 expression. Arrows indicate the podocytes expressing Prdx2 and arrowheads mark the cleaved
caspase 3 positive-staining podocytes after Ang II administration. (e) Quantitative analysis of immunohistochemical staining. Expressions of
Prdx2 and cleaved caspase 3 were evaluated by counting glomerular positive-staining podocytes in Ang II– and vehicle-infused rat kidneys.
At least six kidneys were used for one experimental group, and at least 50 glomeruli were counted in each kidney. The numbers of positive-
staining cells per glomerular section were calculated and represented as means±s.e.m. (#statistically significant with Po0.05 compared
with vehicle-treated rats).
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Gel plugs were digested with trypsin (Promega, Mannheim,
Germany), and peptides were extracted and analyzed with an
UltraflexIII matrix-assisted laser desorption ionization time-of-
flight mass spectrometer (Bruker Daltonics, Bremen, Germany)
operating in reflection positive-ion mode. The Swiss-Prot database
was searched with GPS Explorer software (Applied Biosystems,
Carlsbad, CA) and the MASCOT search engine (Matrix Sciences,
London, UK) to identify peptide mass data acquired using
matrix-assisted laser desorption ionization time-of-flight mass
spectrometry. A peptide group was considered a positive match
for a database protein when the confidence interval for the match
was at least 95% as determined by GPS Explorer, and when the spot
position on the 2D gel reflected approximately the theoretical
isoelectric point and molecular weight of the specified protein.
MASCOT scores 461 were considered significant (Po0.05).
Western blotting
Cultured podocytes or rat kidney tissues were washed with ice-cold
phosphate-buffered saline (PBS) and homogenized in ice-cold lysis
buffer (12mmol/l Tris-base, 8mmol/l HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid), 50mmol/l NaCl, 15mmol/l KCl,
1.5mmol/l MgCl2, 1mmol/l ethylene glycol tetraacetic acid,
10mmol/l Na2H2P2O7, 1mmol/l ATP, 20mmol/l NaF, 1mmol/l
Na3VO4, 1% Triton X-100, and complete protease inhibitor) on ice.
The lysates were centrifuged for 1 h at 16,000g. Supernatant pro-
tein concentrations were measured using Advanced Protein Assay
agents. Equal amounts of protein extract were resolved by SDS-
polyacrylamide gel electrophoresis and immunoblotted. Chemi-
luminescent signals (LumiLight, Roche Diagnostics) were detected
with a Lumi-Imager or X-ray films and quantified using the
LumiAnalyst program (Roche Diagnostics, Mannheim, Germany).
Immunofluorescent staining, immunohistochemistry, and
transmission electron microscopy
Kidney tissue was placed on glass slides, air dried, and then washed
three times with PBS. Bovine albumin solution (4%) in PBS was
applied to block nonspecific endogenous antigens. The unlabeled
primary antibodies (detecting Prdx2, podocin, or Wilms’ tumor-1)
were applied in volumes of 50–100 ml using Pasteur pipettes. The
glass slides were placed in the staining box and incubated for 1 h at
room temperature or overnight at 4 1C. After three more 5-min PBS
washes, fluorophore-labeled secondary antibodies were applied and
reacted in the same manner as the primary antibodies. After three
more 5-min PBS washes, the specimen was mounted and glass
coverslips were attached for visualization under a fluorescent
microscope (Axiovert 100, Zeiss, Oberkochen, Germany).
Paraffin-embedded formalin-fixed 3-mm-thick kidney sections
from Ang II–infused and control rats were deparaffinized, treated
with 0.3% H2O2 to block endogenous peroxidase activity, and
microwaved for two consecutive 10-min periods at 500W and 250W,
respectively. The sections were then incubated with antibody to Prdx2
or cleaved caspase 3. Immunoperoxidase staining was performed
using the Vecstain ABC kit (Vector laboratories, Burlingame, CA)
according to the manufacturer’s instructions. The immunoperoxidase
staining was performed using diaminobenzidine (Sigma-Aldrich).
Generation of Prdx2 knockdown podocytes
The RNA interference method (siRNA) was based on the GenScript
retroviral siRNA expression vector (pRNA-H1.4/retro) and per-
formed as directed by technical manual no. 0187 (GenScript,
Piscataway, NJ). A small DNA insert (roughly 70–80 base pairs,
designed husing GenScript’s siRNA Target Finder and siRNA
Construct Builder) encoding a short hairpin RNA targeting the
gene of interest was cloned into this vector between the MluI and
XhoI sites. The sense oligonucleotide sequences of the short hairpin
RNA insert targeting mouse Prdx2 (NM_011563; GeneID:21672)
and peroxiredoxin 1 (NM_011034; GeneID:18477) were 50-ACTCT
CAGTTCACCCACCT-30 and 50-CCACGGAGATCATTGCTTT-30,
respectively. The RNA short hairpin gene-containing viruses were
produced by co-transfecting HEK293 cells with three plasmids
(2.5 mg pMD.G, 7.5mg pMD.gag/pol, and 10 mg pRNA-TH1.4/Retro-
mPrdx) using the calcium phosphate method. The remaining
retroviral gene delivery procedures were performed exactly as
described previously.10 Podocytes infected with the virus soup were
selected with hygromycin (25 mg/ml) beginning 4 days after viral
transduction to obtain 100% positive cells.
ROS measurement by DHE assay
ROS (mainly superoxide, O2
 ) generation in adherent cultured
podocytes was estimated by DHE staining as described previously.45
Briefly, podocytes cultured on glass coverslips were loaded with
10 mmol/l DHE in HEPES buffer for 30min at 38 1C under 5% CO2.
After staining, the cultures were washed briefly with PBS and
mounted. The stained cells were examined at excitation/emission
wavelengths of 560/660 nm using an inverted fluorescence micro-
scope (Axiovert 100, Zeiss). Image analysis was performed using
ImageJ software (NIH, Bethesda, MD). Total cell numbers and DHE
fluorescence intensity of each cell were counted and quantified in six
separate fields (75–100 cells per field) for each of the conditions. The
relative fluorescence intensity was calculated by dividing the total
integrated optical density by the total number of cells in each field.
Mean fluorescence intensity measurements were obtained from
three separate experiments in each group.
Quantification of apoptosis and necrosis by flow cytometry
Apoptosis was determined by detecting Annexin V binding using
flow cytometry as described previously.46 After 24-h incubation with
the indicated stimuli, cultured podocytes were harvested using cold
PBS on ice, scraped, and collected by centrifugation. Cells were
washed with staining buffer and incubated with 5 ml Annexin
V-FITC and 5 mg/ml PI in 100 ml of staining buffer for 30min at
4 1C in the dark. Cells were washed again, resuspended in 250ml
of staining buffer, and analyzed by flow cytometry on a FACScan
flow cytometer (Becton-Dickinson, Mountain View, CA). A total
of 10,000 events were triggered by forward-scatter and side-scatter
light and the samples were analyzed using CellQuest software
(Becton-Dickinson). Cells that stained positive for Annexin V-FITC
and negative for PI were considered apoptotic.
Statistical analyses
All data are represented as means±s.e.m. unless otherwise specified.
Group differences were tested by Student’s t-test. Comparisons
involving more than two groups were performed using two-way
analysis of variance (SPSS, Chicago, IL). The level of statistical
significance was set to Po0.05.
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